Sarcoidosis

Overview

Sarcoidosis is an inflammatory disease in which immune cells form small clumps called granulomas, most often in the lungs and nearby lymph nodes but potentially in the skin, eyes, heart, nervous system, liver, kidneys, and other organs. Its cause remains unknown; inherited susceptibility and environmental or infectious triggers are thought to interact. It can affect people of any age and is more common among people of African or Scandinavian descent. Sarcoidosis overview

The outlook is highly variable. Some people have spontaneous remission without treatment, while others develop persistent inflammation, lung scarring, or potentially life-threatening heart, neurologic, or other organ involvement. Treatment is therefore aimed at protecting organs and improving quality of life, rather than curing the underlying disease: prednisone and other corticosteroids remain the usual first-line drugs, followed when needed by steroid-sparing immunosuppressants such as methotrexate or anti-tumor-necrosis-factor (anti-TNF) medicines. ATS treatment guide ERS treatment guideline

Scope of Recent Research (2020–present)

Research activity since 2020 has intensified around identifying the immune circuits that create and sustain granulomas, finding biomarkers that distinguish active from self-limited disease, and testing targeted treatments that can replace long-term steroids. The field has produced credible signals for JAK inhibition, mTOR inhibition, and macrophage-directed approaches, but no intervention has yet reproducibly eliminated the cause of sarcoidosis or demonstrated a broadly applicable, durable medication-free cure in controlled trials. Targeted-therapy meta-analysis FSR research grants

Major Breakthroughs and Emerging Therapies

JAK inhibition. Janus kinase (JAK) inhibitors block intracellular signaling used by inflammatory cytokines, including interferon-gamma. In a small prospective pulmonary-sarcoidosis study, three of five corticosteroid-dependent participants met the prespecified endpoint of at least a 50% steroid reduction without worsening lung function or respiratory symptoms after 16 weeks of tofacitinib. Tofacitinib pulmonary proof-of-concept In a separate open-label study of ten people with cutaneous sarcoidosis, all improved and six achieved complete skin responses; molecular analyses linked improvement to suppression of type-1 immune activity, particularly interferon-gamma-associated signaling. Tofacitinib and type-1 immunity These results are promising but remain too small and uncontrolled to establish a cure or routine use across organ types.

mTOR and immunometabolism. Researchers have found that sarcoid granulomas contain metabolically altered macrophages and activated mechanistic target of rapamycin (mTOR) signaling. In a 2024 single-center trial of persistent, steroid-refractory cutaneous sarcoidosis, oral sirolimus, an mTOR inhibitor, improved clinical and biopsy findings in seven of ten participants in the systemic-treatment phase; topical sirolimus did not significantly improve lesions. Sirolimus trial in cutaneous sarcoidosis Complementary single-cell and spatial-transcriptomic work has identified metabolically reprogrammed macrophages, inflammatory T cells, fibroblasts, cytokine pathways, and tissue-remodeling programs as components of granuloma formation, creating a rationale for more precise metabolic and immune-targeted combinations. Single-cell spatial granuloma study

Macrophage and cytokine targeting. Efzofitimod is an investigational biologic intended to modulate neuropilin-2 on immune cells, including macrophages. Its earlier phase 1b/2a study reported dose-related signals in quality of life, steroid reduction, and lung function, supporting advancement to phase 3. Efzofitimod early clinical study However, the subsequent EFZO-FIT phase 3 trial did not meet its primary endpoint of reducing average oral corticosteroid dose at week 48, despite nominal secondary signals in patient-reported lung health and steroid withdrawal; it should therefore not be considered a proven disease-modifying therapy. EFZO-FIT topline results

Experimental nucleic-acid and cell-migration approaches. In preclinical work, inhaled lipid nanoparticles carrying plasmid DNA for legumain reduced granulomas in two mouse models by shifting macrophage behavior away from a highly inflammatory state. Legumain nanoparticle study Other translational research identified CXCR4-associated recruitment of type-1 innate lymphoid cells in sarcoid skin and lung granulomas; blocking CXCR4 or these cells reduced granuloma formation in a mouse model. CXCR4 and innate lymphoid cells These are mechanistically important leads, but neither gene delivery nor cell therapy has entered established human curative testing for sarcoidosis.

Clinical Trials and Experimental Approaches

Efzofitimod was the largest recent interventional pulmonary-sarcoidosis program. Sponsored by aTyr Pharma, the completed 268-participant EFZO-FIT study was a randomized, double-blind phase 3 trial comparing intravenous efzofitimod doses of 3 mg/kg and 5 mg/kg with placebo over 48 weeks in people receiving corticosteroids. EFZO-FIT registry record The sponsor reported in September 2025 that the trial missed its primary corticosteroid-dose endpoint; the favorable secondary findings were nominal because the primary endpoint was not met. EFZO-FIT topline results

Negative trials have also provided useful evidence about which biological targets may be insufficient on their own. Kinevant Sciences’ RESOLVE-Lung phase 2 trial randomized 107 people with chronic active pulmonary sarcoidosis to anti-GM-CSF antibody namilumab or placebo while background treatment was reduced; namilumab did not provide clinical benefit and had more rescue events numerically than placebo. RESOLVE-Lung trial A Stanford-led phase 2 randomized-withdrawal study of the interleukin-6 receptor blocker sarilumab enrolled 15 people with glucocorticoid-dependent sarcoidosis and found no meaningful improvement signal, although the small sample prevents firm conclusions. Sarilumab phase 2 trial

Methodologies and Scientific Approaches

Researchers are increasingly pairing patient-derived material with functional models. These include blood immune cells stimulated to form granulomas in culture, bronchoalveolar-lavage samples from the lung, tissue biopsies, humanized or antigen-induced mouse models, and high-resolution single-cell and spatial RNA sequencing. Such platforms help identify which macrophage, T-cell, fibroblast, metabolic, and cytokine programs differ between progressive and non-progressive disease, then test whether inhibiting a candidate pathway reduces granuloma formation. βc-receptor preclinical model Single-cell lung immune-cell study

Biomarker development is also becoming central to cure-oriented research because a trial cannot demonstrate durable remission without reliably measuring active disease. A 2024 study used phage-display discovery and a peptide enzyme-linked immunosorbent assay to identify two candidate blood immunoepitopes; in 386 participants, combined markers differentiated sarcoidosis from healthy controls, tuberculosis, and lung cancer in cross-validation. This assay requires independent validation before clinical use, but it could eventually improve diagnosis, treatment selection, and relapse monitoring. Peptide-based sarcoidosis immunoassay

Leading Institutions and Funding

Important academic contributors include Oregon Health & Science University and collaborators in JAK-inhibitor studies, the Medical University of Vienna and CeMM in mTOR and immunometabolism research, the University of Pennsylvania in innate-lymphoid-cell biology, Wayne State University and the University of California, San Francisco in antigen and diagnostic research, and Cleveland Clinic investigators in multinational pulmonary-sarcoidosis trials. Tofacitinib pulmonary proof-of-concept Sirolimus trial in cutaneous sarcoidosis CXCR4 and innate lymphoid cells Peptide-based sarcoidosis immunoassay

The U.S. National Heart, Lung, and Blood Institute supports sarcoidosis through its Granulomatous and Interstitial Lung Disease Program, including work on genetics, pathogenesis, biomarkers, patient cohorts, and interventional studies. NHLBI granulomatous-lung-disease program The Foundation for Sarcoidosis Research supplements this ecosystem with $100,000 two-year pilot and cardiac grants and a $200,000 two-year established-investigator grant; recent awardees include projects on fibrotic progression, cell-free DNA in neurosarcoidosis, and type-1 innate lymphoid cells. FSR grants FSR pilot awards

Strengths, Limitations, and Challenges

The major strength of current research is its move from broad immune suppression toward mechanisms directly linked to granuloma biology: interferon/JAK signaling, macrophage polarization, mTOR-driven metabolism, cytokine networks, and immune-cell trafficking. Small studies of tofacitinib and sirolimus show that targeted suppression can sometimes permit steroid reduction or sustained clinical improvement, while medication-free remission after anti-TNF therapy has been documented in selected patients. Tofacitinib pulmonary proof-of-concept Sirolimus trial in cutaneous sarcoidosis Medication-free remission after anti-TNF therapy

The central limitations are disease heterogeneity, uncertain initiating causes, small trials, different organ manifestations, imperfect activity measures, and the possibility that inflammation, established fibrosis, and irreversible organ damage need different treatments. The recent negative namilumab, sarilumab, and efzofitimod results show that biologically plausible single-target therapies may not overcome redundant immune pathways or produce large enough benefits in mixed patient populations. RESOLVE-Lung trial Sarilumab phase 2 trial EFZO-FIT topline results Long-term infection, malignancy, metabolic, reproductive, and access concerns also matter for immunosuppressive targeted therapies, particularly if they must be taken indefinitely.

Outlook and Future Directions

As of October 28, 2026, a universal cure for sarcoidosis is not close: no therapy has been shown in robust controlled trials to remove the initiating cause, prevent relapse across disease forms, and restore durable medication-free health for most patients. The nearer-term milestones are validated biomarkers of active and progressive disease, organ-specific trials that enroll biologically defined subgroups, larger randomized studies of JAK and mTOR inhibition, and confirmation that a treatment can maintain remission after withdrawal. A realistic first “curative” advance may therefore be durable, biomarker-confirmed, medication-free remission in a defined subgroup rather than a single therapy that cures every form of sarcoidosis. Targeted-therapy meta-analysis Multi-omic progression signatures

References

• Sarcoidosis overview — National Institutes of Health, 2026.
• ATS treatment guide — American Thoracic Society, 2026.
• ERS treatment guideline — Baughman et al., 2021.
• Targeted-therapy meta-analysis — Thorax, 2025.
• FSR research grants — Foundation for Sarcoidosis Research, 2026.
• Tofacitinib pulmonary proof-of-concept — Friedman et al., 2021.
• Tofacitinib and type-1 immunity — Damsky et al., 2022.
• Sirolimus trial in cutaneous sarcoidosis — Redl et al., 2024.
• Single-cell spatial granuloma study — Krausgruber et al., 2023.
• Efzofitimod early clinical study — Baughman et al., 2023.
• EFZO-FIT registry record — ClinicalTrials.gov, 2026.
• EFZO-FIT topline results — aTyr Pharma, 2025.
• Legumain nanoparticle study — Zhang et al., 2026.
• CXCR4 and innate lymphoid cells — Sati et al., 2024.
• RESOLVE-Lung trial — Van den Blink et al., 2026.
• Sarilumab phase 2 trial — Baker et al., 2024.
• βc-receptor preclinical model — Drake et al., 2026.
• Single-cell lung immune-cell study — Liu et al., 2026.
• Peptide-based sarcoidosis immunoassay — Peng et al., 2024.
• NHLBI granulomatous-lung-disease program — National Heart, Lung, and Blood Institute, 2026.
• FSR grants — Foundation for Sarcoidosis Research, 2026.
• FSR pilot awards — Foundation for Sarcoidosis Research, 2026.
• Medication-free remission after anti-TNF therapy — Yee, 2023.
• Multi-omic progression signatures — Baughman et al., 2024.